VISIGALLI, DAVIDE
 Distribuzione geografica
Continente #
EU - Europa 1.746
Totale 1.746
Nazione #
IT - Italia 1.746
Totale 1.746
Città #
Genova 1.166
Rapallo 265
Genoa 248
Vado Ligure 65
Bordighera 2
Totale 1.746
Nome #
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 142
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 138
Hind limb unloading of micemodulates gene expression at the protein and mRNA level in mesenchymal bonecells. 132
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy 129
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 116
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 113
The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts 110
Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 98
PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker 97
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 91
P2X7 antagonism in experimental CMT1A: a potential therapeutic strategy 90
Oxydative phosphorilation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 86
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 82
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 76
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A 67
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 65
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 61
null 48
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 27
DEVELOPMENT AND VALIDATION OF A BIOMARKERS PANEL TO CAPTURE PATHOPHYSIOLOGICAL HETEROGENEITY OF GBS AND CIDP PATIENTS 20
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome 8
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS 3
Totale 1.799
Categoria #
all - tutte 5.963
article - articoli 5.477
book - libri 0
conference - conferenze 486
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.926


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020369 0 0 11 18 27 46 69 36 37 75 40 10
2020/2021106 5 11 5 21 6 7 6 11 11 10 8 5
2021/2022239 12 9 18 24 4 17 9 66 16 18 6 40
2022/2023302 22 34 2 23 53 40 4 27 52 0 43 2
2023/2024194 6 20 7 26 17 32 28 5 7 7 6 33
2024/202596 51 32 13 0 0 0 0 0 0 0 0 0
Totale 1.799